NEVERMINED-AG
12.7.2022 15:02:09 CEST | Business Wire | Press release
Nevermined AG , a Web3 company that provides tools to read, write and own your digital assets, announced their initial investment round of €3 million, co-led by Signature Ventures and Polymorphic Capital. The Nevermined platform consists of modular solutions that easily allow users the ability to create and monetize digital assets and participate in the read-write-own vision of Web3.
The platform offers the foundations for building digital ecosystems with components like Tokenization Engine, Marketplace Creator, Royalties Engine, Decentralized Access Control, DAO Framework and DISC, or Data In-Situ Computation, for Remote Computation.
Nevermined CEO Don Gossen shares, “The best internet is the one that everyone can access and own. And this is what Nevermined allows people to do. When it comes to Data mixed with Web3 our pedigree speaks for itself – our team has been working with cutting-edge tech for over 20 years, first in Big Data, and now in Web3. With these building blocks, we can help you realize your vision. I’d argue we’re the best team in the world that does what we do.”
According to a new report by Grand View Research , the global blockchain technology market size is expected to reach $1,431 billion by 2030. With this market opportunity and its solid, proven technology, Nevermined will leverage this capital raise to:
Be more complete and scalable by advancing its product roadmap: Nevermined will enhance its digital asset development platform that makes Web3 accessible by streamlining the creation, monetization and management of decentralized digital assets. Some key projects include:
- Enterprise: A global energy company used the platform to create a peer-to-peer carbon certificate trading marketplace.
- Creative: Autonomies is using Nevermined to build a music NFT platform and DAO, allowing for fairer value distribution between musicians, labels and collectors.
- Science: In a world first, VitaDAO used Nevermined to tokenize the IP of scientific research, conducted by the Scheibye-Knudsen Lab in Copenhagen.
Be more accessible by accelerating global footprint: To foster company growth and better customer experience, Nevermined will be strengthening its presence in key areas including product, engineering, marketing and community.
Be easier to use by expanding the breadth and depth of the partner ecosystem: Nevermined will establish both technical and creative partnerships that will bolster its mission. Along with deepening partnerships with initiatives such as Autonomies , a music NFT platform allowing artists to become stakeholders.
“We only invest in outstanding teams that build the backbone of the decentralized future,'' said Managing Director Juliane Hahn, Signature. “We see many startups that try to combine Data with Blockchains. Nevermined is the first company that understands the complexities and provides actual solutions at the intersection of Data and Web3. In the future every data-driven company will require the ability to turn their data silos into data ecosystems. Nevermined delivers the full product stack to do just that.”
“We’ve been very impressed with the Nevermined team,” said Vitaly Spassky, founder of Polymorphic Capital. “They have the vision, as well as the tech talent and pedigree to execute. To us digital assets are a crucial building block for the decentralized web. And the Nevermined platform makes it super easy for teams and projects to integrate Web3 tech. We’re very excited to see what people will build with Nevermined.”
Nevermined began as an incubation project within Keyko AG to solve issues around data sharing using tokenization and smart contract gateways. From there it evolved from a data-centric solution to a decentralized digital assets solution with much broader applicability.
About Nevermined
Nevermined is a Web3 company that provides tools to read, write and own your digital assets, founded by CEO Don Gossen, CTO Aitor Argomaniz and CIO Dimitri De Jonghe. They met while creating Ocean Protocol, the world’s first decentralized data marketplace. In 2019, they founded Keyko over a shared belief in the power of digital ecosystems. They helped a variety of organizations develop Web3 ecosystems, worth a combined value of $3 billion. In 2022, they decided to spin out Nevermined as a standalone technology platform.
More info on https://nevermined.io/
About Signature Ventures
Signature Ventures is an early-stage Venture Capital fund investing in Blockchain, Distributed Ledger Technology and Web3 technology. Based in Germany, the fund invests in Pre-Seed to Series A, globally with a focus on Europe. Signature Ventures is managed by Juliane Hahn, Founding Partner, and Dr. Georg Stricker, Tech Partner. They combine an extensive track record of VC investments with deep Blockchain expertise.
About Polymorphic Capital
Polymorphic Capital is a venture capital firm that invests globally in teams creating the future of the internet with decentralized protocols and digital assets. They specialize in infrastructure, finance and gaming.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005503/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom